H.C. Wainwright reiterates a Buy rating on uniQure (QURE) with a $70 price target after the company announced data from the first mesial temporal lobe epilepsy patient treated with AMT-260. These early data, while from only one patient, are encouraging, and support advancement of the program to additional patients with drug-refractory mTLE who have no available treatment options, the analyst tells investors in a research note. The firm believes that if AMT-260’s early safety profile is confirmed in additional patients, uniQure may advance the program to the randomized Phase 2 portion of the trial in 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- uniQure presents case study of first patient dosed with AMT-260
- Unusually active option classes on open May 21st
- uniQure’s Clinical and Regulatory Progress Drives Buy Rating Amid Market Overreaction
- Optimistic Buy Rating on uniQure Amidst Progress in Huntington’s Disease Program and AMT-130 Developments
- uniQure N.V. Earnings Call: Progress Amid Challenges